Role of Tryptase Levels in Patients With Stable Coronary Artery Disease.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-12

Study Completion Date

2027-01-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to measure the levels of serum tryptase and correlate them with the severity of coronary artery disease in study population. In addition, it will evaluate the usability of tryptase levels as a prognostic biomarker for future cardiovascular events.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tryptase and Coronary Heart Disease

NCT01618279

Acute Coronary Syndrome With ST Elevation on Electrocardiogram Acute Coronary Syndrome Without ST Elevation on Electrocardiogram Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent +1 more

COMPLETED

Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome

NCT01698021

Acute Coronary Syndrome Myocardial Infarction Unstable Angina

UNKNOWN

Regulation and Signaling of Red Blood Cell (RBC) Endothelial Nitric Oxide Synthase (eNOS) in Patients With Stable and Unstable Coronary Artery Disease

NCT02265016

Coronary Artery Disease Endothelial NO-synthase

COMPLETED

Novel Biomarkers in Patients With Acute Myocardial Infarction

NCT05791916

Cardiovascular Diseases Myocardial Infarction Acute Coronary Syndrome +1 more

RECRUITING

Natural History of Carotid Atherosclerosis

NCT01521351

Carotid Artery Disease Stroke Myocardial Infarction +1 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Coronary artery disease (CAD) is the leading cause of death worldwide based on WHO' s latest review in 2019 with CAD being responsible for the 16% of them. The main feature of coronary artery disease is the accumulation of atherosclerotic plaque in the epicardial arteries whether obstructive or non-obstructive. CAD is further subclassified into Chronic Coronary Syndrome (CCS) and Acute Coronary Syndrome (ACS). Patients with CCS experience long and stable periods of myocardial ischemia. However, in the case of a plaque rapture these patients can turn into ACS patients. The objective of this study is to predict that sudden shifting of patients from CCS to ACS by associating the role of inflammation and its factors with cardiovascular events. In particular, it focuses on mast cell (MC) tryptase which provokes plaque instability in patients with CCS. Mast cells needs to be activated to release tryptase and their activation mechanism seems to be the bridging point between tryptase and coronary artery disease. Previous studies have shown that IgE levels, which is the most potent activator of MC, are found high in hyperlipidemic patients. In addition, oxidized LDL (Ox-LDL) is another MC activator.

In reference to the fact that there might be a correlation between tryptase and coronary plaque instability in patients with chronic coronary syndrome, the investigator propose an interventional study for the role of tryptase as a prognostic biomarker in patients with CCS by studying a large population of Greek subjects with CCS.

The study will be conducted on 2 patient population:

1. Patients without coronary artery disease (estimated stenosis \<70%) - Control group
2. Patients with coronary artery disease (estimated stenosis \>70%) - CAD group

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Coronary Artery Disease Group

Patients with angiographically proven coronary artery stenosis \>70%

No interventions assigned to this group

Non-coronary Artery Disease Group

Patients with angiographically proven coronary artery stenosis \<70%

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects aged 18 - 85 years old.
* Clinical symptoms of angina which are classified based on the Canadian Cardiovascular Score (CCS score)
* Positive SPECT scan for myocardial ischemia

Exclusion Criteria

* Acute Coronary Syndrome 4 weeks before the coronary catheterization
* Percutaneous Coronary Angioplasty
* Coronary Artery Bypass Graft
* Active symptoms of allergy (asthma, urticaria)
* Mastocytosis
* Hypereosinophilia
* Autoimmune disease
* Cancer
* Kidney failure
* Myelodysplastic Syndrome
* Denial of signing informed consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No